Navigation Links
Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
Date:1/12/2009

PHILADELPHIA and LONDON, Jan. 12 /PRNewswire-FirstCall/ -- Thomson Reuters today announced that it has published a new white paper on the topic of biomarkers drawing on expert insight from academics and key players in the pharmaceuticals industry. Called "Biomarkers: An Indispensable Addition to the Drug Development Toolkit," it explores the role of biomarkers as evaluative tools in addressing some of the challenges seen in clinical research and their potential to improve decision making, accelerate drug development and reduce development costs.

Used as a way to measure normal biological processes in the body, pathological processes, or the response of the body to a therapeutic intervention, Biomarkers have become an essential part of clinical development because they potentially offer a faster route to market versus the conventional drug development approach, where success rates have steadily declined in recent years. Attrition rates for drugs in discovery and development are currently very high with less than 10% of tested products entering phase I trials. With increasing costs involved in the drug development process, and growing concern that fewer drugs are making it through to the marketplace each year, the pharmaceutical industry is embracing biomarkers as a way of predicting a drug candidate's performance early and with a greater degree of certainty.

"The FDA, as well as academic and research organizations, have recognized Biomarkers as having great potential to speed the development and approval of medical products," said Wendy Hamilton, vice president of product strategy and marketing, Scientific business of Thomson Reuters. "Because biomarkers can predict drug efficacy and safety more quickly than conventional clinical endpoints, they hold the potential to substantially accelerate product development, and because they help to identify earlier those drug candidates that are likely to fail, they reduce drug development costs. In addition, biomarkers could revolutionize therapeutic treatments in areas such as oncology, with their capacity to tailor therapies to specific individuals."

"Biomarkers such as Her2 have already shown their effectiveness and benefit in clinical trials," said Colin Williams, product manager, biology & bioinformatics, Scientific business of Thomson Reuters. "Many other biomarkers are following suit in clinical research but selecting the correct biomarker can be a real challenge. Identifying the correct biomarker in clinical studies can mean the difference between a drug candidate being approved or not, which has profound implications for both the patients awaiting treatment and the financial security of the drug company involved."

Thomson Reuters has expanded the availability of BIOMARKERcenter, its unique comprehensive resource for biomarker intelligence. BIOMARKERcenter is now available through several delivery options: as a subscription option to users of Prous Science Integrity(R), as an XML feed for in-house bioinformatics solutions and also as a standalone web application. This solution covers biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas and is the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker. BIOMARKERcenter is the most comprehensive resource of its kind and continues to expand rapidly, with more than 2,000 different biomarkers, and 13,000 unique uses of these biomarkers within its database.

For further information about BIOMARKERcenter, please go to: http://scientific.thomsonreuters.com/products/biomarkercenter/

To read the full white paper, "Biomarkers: an indispensable addition to the drug development toolkit," please register online at: http://scientific.thomsonreuters.com/forms/biomarkers/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lupus is a Significant Cost to Employers, According to Thomson Reuters Study
2. Clinical Xpert Navigator From Thomson Reuters Is Named Best Mobile Data System in the KLAS Awards - for Seventh Consecutive Year
3. BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy
4. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
5. Parrish Medical Center Deploys Clinical Xpert(TM) Solutions from Thomson Reuters
6. Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders
7. Thomson Reuters Survey Finds Cancer Patients Forgoing Treatment Because of Cost
8. The Scientific Business of Thomson Reuters Predicts Nobel Laureates
9. Indonesias Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
10. The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
11. Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: